OMS-906 Sales Forecast, and Market Size Analysis - 2034
상품코드:1909215
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
OMS-906 성장 촉진요인
1. 시장 점유율 확대와 신규 환자 수 증가
OMS-906은 급성 관상동맥 증후군(ACS) 치료를 목표로 하는 잠재적 최초 경구용 항혈소판제로, 현재 병원 환경에서 정맥주사제가 주류를 이루는 부문에 진입할 수 있는 위치에 있습니다.
신규 환자 투여는 응급 및 조기 중재적 사용에 의해 주도될 것으로 예상되며, 특히 OMS-906이 카테터실 외부에서 더 빠른 치료 시작을 가능하게 할 경우 더욱 그러할 것입니다.
심장 전문의 및 응급의학 전문의들의 관심 증가는 약물의 빠른 작용 발현과 경구 투여 방식이 결합되어 현재 정맥 주사 요법의 주요 한계를 해결한다는 점에서 뒷받침됩니다.
Omeros의 전략은 조기 혈소판 억제와 워크플로우의 단순화를 위해 인터벤션 심장병과 응급의료 관계자들에게 계발에 중점을 둡니다.
2. 주요 적응증의 확대
급성 관상동맥 증후군(주요 적응증) : OMS-906은 심근경색을 포함한 ACS 환자를 대상으로 개발 중이며, 이 경우 즉각적인 혈소판 억제가 매우 중요합니다.
병원 전 및 초기 병원 환경 : 경구 투여 특성으로 치료 경로 초기에 조기 투여가 가능해 기존 카테터실 환경을 넘어 사용이 확대될 수 있습니다.
경피적 관상동맥 중재술(PCI) 지원 : OMS-906은 PCI 시술 시 정맥 내 GP IIb/IIIa 억제제의 대체 또는 보완제로 포지셔닝될 수 있습니다.
파이프라인 및 수명 주기의 기회는 보다 광범위한 혈전성 심혈관 질환의 적응증을 포함하며 장기적인 시장 확대가 기대됩니다.
3. 지리적 확대
OMS-906은 세계의 심혈관 시장을 시야에 넣어 개발이 진행되고 있으며, 당초는 ACS의 발생률이 높고, 인터벤션 심장 치료의 인프라가 정비되고 있는 미국 및 유럽에 초점을 맞추었습니다.
아시아태평양은 심혈관 질환 유병률 증가, PCI 시술량 확대, 첨단 심장 치료 접근성 개선에 힘입어 의미 있는 성장 기회를 제공합니다.
Omeros는 보다 광범위한 지역의 채택을 지원하기 위해 전략적 제휴 및 지역별 규제 당국과의 협력을 추진할 전망입니다.
4. 신규 적응증 승인
급성 관상동맥증후군(ACS)에 대한 OMS-906의 규제 승인은 GP IIb/IIIa 억제 부문에서 제한적이었던 혁신을 크게 확대할 것입니다.
앞으로는 인접한 혈전성 질환이나 인터벤셔널 심장병학의 영역으로 적응 확대가 진행되면 수익원의 다양화와 경쟁력의 강화가 기대됩니다.
보다 안전하고 편리한 항혈소판제에 대한 높은 미충족 요구를 고려하면, OMS-906은 임상적 차별화를 인정하는 규제 경로의 승인이 기대됩니다.
5. 심혈관 영역의 견조한 판매량 추이
심혈관 질환은 전 세계적으로 가장 높은 치료 수요를 보이는 부문 중 하나로, 급성 관상동맥증후군(ACS)이 응급 입원의 상당 부분을 차지합니다.
PCI 절차와 조기 개입 전략의 지속적인 증가는 효과적인 혈소판 억제에 대한 지속적인 수요를 지원합니다.
OMS-906은 조기 개입과 급성기 치료 과정의 효율성에 대한 동향을 따르며, 승인되면 미래 치료 건수 증가를 뒷받침할 수 있습니다.
6. 경쟁 우위성과 시장 동향
OMS-906은 경구 투여의 저분자 GP IIb/IIIa 억제제라는 특성에 의해 abciximab이나 eptifibatide 등의 기존의 정맥내 투여 약제와는 차별화되고 있습니다.
지속적 주입 없이도 신속한 혈소판 억제가 가능하다는 점은 업무 효율성과 환자 관리 개선으로 이어질 수 있습니다.
급성 치료 간소화, 경구제 선호, 가치 기반 심혈관 치료와 같은 광범위한 시장 동향은 OMS-906의 포지셔닝을 뒷받침합니다.
심혈관 결과에서 실제 임상 증거(RWE)의 중요성이 증가함에 따라 시간이 지남에 따라 지불자와 의료 제공업체의 신뢰를 얻을 수있을 것으로 기대됩니다.
본 보고서는 주요 7개국(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)에서 발작성 야간 혈색소뇨증 및 사구체 신염과 같은 잠재적 적응증에 대한 OMS-906의 종합적인 인사이트를 제공합니다. 본 보고서는 2020년부터 2034년까지의 조사 기간 동안 주요 7개국에서 OMS-906의 기존 승인 및 신규 적응증의 사용 상황과 잠재적 적응증의 성과에 대한 상세한 전망을 제공합니다. 또한 OMS-906의 판매 예측, 작용기전(MoA), 투여량 및 투여 방법, 규제상의 이정표를 포함한 R&D 및 기타 개발 활동에 대한 인사이트를 제공합니다. 또한 과거 및 현재 OMS-906의 실적, 7개국 시장 예측 분석을 포함한 미래 시장 평가, SWOT 분석, 분석가 견해, 경쟁업체의 종합적 개요, 각 적응증에 대한 기타 신흥 치료법에 대한 개요도 포함되어 있습니다. 또한 OMS-906의 매출 예측 분석, 시장 주도 요인 등도 정리했습니다.
목차
제1장 보고서 개요
제2장 발작성 야간 혈색소뇨증이나 사구체 신염 등의 잠재적 적응증에 대한 OMS-906의 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 프로파일
제3장 OMS-906 : 경쟁 구도(시판 중인 치료제)
제4장 OMS-906 : 경쟁 구도(개발 후기 치료제)
제5장 OMS-906 : 시장 평가
승인 및 잠재적 적응증에 대한 시장 전망
주요 7개국 분석
승인 및 잠재적 적응증에 대한 주요 7개국 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 OMS-906 : SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 정보
제12장 보고서 구매 옵션
HBR
영문 목차
영문목차
Key Factors Driving OMS-906 Growth
1. Market Share Gains and New Patient Starts
OMS-906 is positioned as a potentially first-in-class oral antiplatelet therapy designed to address acute coronary syndromes (ACS), an area dominated by intravenous agents in hospital settings.
New patient starts are expected to be driven by emergency and early-intervention use, particularly if OMS-906 enables faster initiation of therapy outside catheterization labs.
Growing interest from cardiologists and emergency care physicians is supported by the drug's rapid onset of action combined with oral administration, addressing a key limitation of current IV therapies.
Omeros' strategy focuses on educating interventional cardiology and emergency medicine stakeholders around early platelet inhibition and workflow simplification.
2. Expansion Across Key Indications
Acute Coronary Syndrome (Primary Indication): OMS-906 is being developed for patients presenting with ACS, including myocardial infarction, where immediate platelet inhibition is critical.
Pre-Hospital and Early Hospital Settings: The oral profile may allow treatment initiation earlier in the care pathway, potentially expanding use beyond traditional cath-lab environments.
Percutaneous Coronary Intervention (PCI) Support: OMS-906 may be positioned as an alternative or complement to IV GP IIb/IIIa inhibitors around PCI procedures.
Pipeline and lifecycle opportunities could include broader thrombotic cardiovascular indications, expanding long-term market reach.
3. Geographic Expansion
OMS-906 is being developed with a global cardiovascular market in mind, initially focusing on the United States and Europe, where ACS incidence and interventional cardiology infrastructure are well established.
Asia-Pacific represents a meaningful growth opportunity, driven by rising cardiovascular disease prevalence, increasing PCI volumes, and improved access to advanced cardiac care.
Omeros is expected to pursue strategic partnerships and regional regulatory engagement to support broader geographic adoption.
4. New Indication Approvals
Regulatory approval of OMS-906 in ACS would significantly broaden treatment options in a space that has seen limited innovation in GP IIb/IIIa inhibition.
Future label expansions into adjacent thrombotic or interventional cardiology settings could diversify revenue streams and strengthen competitive positioning.
Given the high unmet need for safer, more convenient antiplatelet agents, OMS-906 may be positioned for regulatory pathways that recognize clinical differentiation.
5. Strong Cardiovascular Volume Momentum
Cardiovascular disease remains one of the highest-volume therapeutic areas globally, with ACS representing a substantial share of emergency admissions.
Continued growth in PCI procedures and early interventional strategies supports sustained demand for effective platelet inhibition.
OMS-906 aligns with trends toward earlier intervention and streamlined acute care pathways, supporting future volume momentum if approved.
6. Competitive Differentiation and Market Trends
OMS-906's oral small-molecule GP IIb/IIIa inhibitor profile differentiates it from existing intravenous agents such as abciximab and eptifibatide.
The potential for rapid platelet inhibition without continuous infusion could improve workflow efficiency and patient management.
Broader market trends-such as simplification of acute care, preference for oral agents, and value-based cardiovascular care-support OMS-906's positioning.
Increasing emphasis on real-world evidence (RWE) in cardiovascular outcomes is expected to support payer and provider confidence over time.
OMS-906 Recent Developments
In December 2025, Omeros Corporation announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 - the most upstream and key activator of the alternative pathway of the complement system - and has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market.
"OMS-906 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of OMS-906 for potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis in the 7MM. A detailed picture of OMS-906's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the OMS-906 for approved and potential indications. The OMS-906 market report provides insights about OMS-906's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OMS-906 performance, future market assessments inclusive of the OMS-906 market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OMS-906 sales forecasts, along with factors driving its market.
OMS-906 Drug Summary
OMS-906 also known as zaltenibart, is a humanized IgG4 monoclonal antibody that selectively inhibits mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of complement factor D (CFD) in the alternative complement pathway (AP). By binding to MASP-3, it prevents CFD maturation, thereby suppressing AP activation upstream, which inhibits both intravascular and extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) more potently than C5 inhibitors, while also showing potential in complement-mediated disorders like C3 glomerulopathy (C3G) and IgA nephropathy (ICGN). Developed by Omeros Corporation (with Novo Nordisk acquiring global rights in 2025 for USD 240 million upfront), it demonstrates dose-proportional pharmacokinetics, rapid suppression of mature CFD, increased hemoglobin, reduced LDH and reticulocytes, and transfusion independence in Phase Ib trials for treatment-naive and ravulizumab-suboptimal PNH patients, administered via intravenous or subcutaneous routes with a long half-life supporting monthly or less frequent dosing. The report provides OMS-906's sales, growth barriers and drivers, post usage and approvals in multiple indications.
OMS-906 is in the Phase II stage of clinical development for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (NCT06298955) and Glomerulonephritis (NCT06209736).
Scope of the OMS-906 Market Report
The report provides insights into:
A comprehensive product overview including the OMS-906 MoA, description, dosage and administration, research and development activities in potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis.
Elaborated details on OMS-906 regulatory milestones and other development activities have been provided in OMS-906 market report.
The report also highlights OMS-906's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The OMS-906 market report also covers the patents information, generic entry and impact on cost cut.
The OMS-906 market report contains current and forecasted OMS-906 sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The OMS-906 market report also features the SWOT analysis with analyst views for OMS-906 in approved and potential indications.
Methodology:
The OMS-906 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OMS-906 Analytical Perspective by DelveInsight
In-depth OMS-906 Market Assessment
This OMS-906 sales market forecast report provides a detailed market assessment of OMS-906 for potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OMS-906 sales data uptil 2034.
OMS-906 Clinical Assessment
The OMS-906 market report provides the clinical trials information of OMS-906 for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
OMS-906 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
OMS-906 Market Potential & Revenue Forecast
Projected market size for the OMS-906 and its key indications
Commercial partnerships, licensing deals, and M&A activity
OMS-906 Clinical Differentiation
OMS-906 Efficacy & safety advantages over existing drugs
OMS-906 Unique selling points
OMS-906 Market Report Highlights
In the coming years, the OMS-906 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The OMS-906 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OMS-906's dominance.
Other emerging products for Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis are expected to give tough market competition to OMS-906 and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OMS-906 in approved and potential indications.
Analyse OMS-906 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted OMS-906 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OMS-906 in approved and potential indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of OMS-906? How strong is OMS-906's clinical and commercial performance?
What is OMS-906's clinical trial status in each individual indications such as Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OMS-906 Manufacturers?
What are the key designations that have been granted to OMS-906 for approved and potential indications? How are they going to impact OMS-906's penetration in various geographies?
What is the current and forecasted OMS-906 market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of OMS-906 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to OMS-906 for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is OMS-906? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. OMS-906 Overview in potential indications like Paroxysmal nocturnal haemoglobinuria and Glomerulonephritis
